Previous 10 | Next 10 |
December 17, 2019 Palm Beach, FL –December 17, 2019 – The success rate for cancer therapies has been limited due to a combination of factors, such as the treatment/drug’s lack of penetration through the blood brain barrier. Reports say that the global drug d...
SAN DIEGO , Dec. 16, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announce...
The following slide deck was published by Heron Therapeutics, Inc. in conjunction with this Read more ...
Under Priority Review status, Health Canada has accepted Heron Therapeutics' (NASDAQ: HRTX ) New Drug Submission (NDS) for HTX-011 for the management of postoperative pain. More news on: Heron Therapeutics, Inc., Healthcare stocks news, Read more ...
SAN DIEGO , Dec. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...
SAN DIEGO , Nov. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...
November 20, 2019 Palm Beach, FL – November 20, 2019 – It appears that the reign of the opioid drugs in the global pain management markets could be coming to an end. While opioids have long been the ‘best’ choice to address the pain patients suffer from var...
Debt is a four letter word and means a four word sentence - Be Prepared for Trouble. " - Lucas Remmerswaal Heron Therapeutics (HRTX) posted Q3 results this week. Both top and bottom line numbers beat the consensus. The shares also saw a rash of Buy reiterations at analyst firms followin...
SAN DIEGO , Nov. 14, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...
SAN DIEGO , Nov. 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Bar...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire SAN DIEGO , May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechn...